5 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 7 Phase 2, 2 Phase 4, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Tacrolimus (TAC): new trials by email Literature Review of Tacrolimus (TAC) trials Research Report on Tacrolimus (TAC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VEL-101 to Prevent Rejection After Kidney Transplantation Tacrolimus (TAC), VEL-101 - Transplantation, Kidney | Phase 2 | Recruiting | Veloxis Pharmaceuticals | 120 | 2026-08-18 | 2026-09-03 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux) - Graft-versus-host Disease (GVHD) | Phase 3 | Recruiting | Incyte Corporation | 572 | 2025-04-02 | 2026-10-22 |
| A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Terminated | ITB-Med LLC | 33 | 2021-06-06 | 2026-03-12 |
| A Dose Escalation Study in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Completed | ITB-Med LLC | 13 | 2021-05-26 | 2025-02-27 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| CCFZ533X2201 - PoC Study in de Novo Renal Transplantation CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF) - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 59 | 2015-02-05 | 2021-09-28 |
| Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Ustekinumab, Placebo, Tacrolimus (TAC) - Graft vs. Host Disease | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 54 | 2013-02-25 | 2020-03-04 |
| A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients Everolimus (EVR), cyclosporine A (CyA), tacrolimus (TAC) - Heart Transplantation | Phase 4 | Completed | Novartis Pharmaceuticals | 162 | 2009-02-24 | 2018-08-07 |
| Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation Tacrolimus (TAC), Methotrexate (MTX), Rapamycin (RAPA) - Acute Graft Versus Host Disease | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 74 | 2008-09-01 | 2015-07-31 |
| A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression Tacrolimus (TAC), Sirolimus, Alemtuzumab - Kidney Transplant Failure and Rejection | Phase 4 | Terminated | Northwestern University | 40 | 2005-04-01 | 2015-10-26 |
Graft vs Host Disease (3) · Anemia, Refractory, with Excess of Blasts (1) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rejection, Psychology (1)
H. Lee Moffitt Cancer Center and Research Institute (2) · ITB-Med LLC (2) · Novartis Pharmaceuticals (2) · Incyte Corporation (1) · Masonic Cancer Center, University of Minnesota (1) · Northwestern University (1) · Veloxis Pharmaceuticals (1)
United States (8) · Germany (2) · Austria (1) · Brazil (1) · Netherlands (1) · Spain (1) · Sweden (1)
Claudio Anasetti, MD (1) · Fredrik Juhlin (1) · Joseph Pidala, MD, MS (1) · Joseph R Leventhal, MD, PhD (1) · Nick Hryciw, MA (1)